Why Roche is excited about Hanmi’s muscle-sparing obesity drug on September 03, 2026 Biologic Preservation Combined CRF2 receptor genentech Glucagon-Like Peptide 1 Hanmi HM17321 lean-mass Muscle function non-incretin therapy Obesity Phase 1 trial Roche (company) +
Roche Bets Up to $2.3 Billion on Hanmi’s Muscle-Preserving Obesity Drug on August 24, 2026 CRF2 receptor genentech Glucagon-Like Peptide 1 Hanmi HM17321 lean-mass Licensing obesity drug Roche (company) urocortin II +